GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (FRA:APH0) » Definitions » EV-to-EBITDA

Ampio Pharmaceuticals (FRA:APH0) EV-to-EBITDA : 0.39 (As of Jun. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ampio Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ampio Pharmaceuticals's enterprise value is €-3.41 Mil. Ampio Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.73 Mil. Therefore, Ampio Pharmaceuticals's EV-to-EBITDA for today is 0.39.

The historical rank and industry rank for Ampio Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:APH0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.89   Med: -0.88   Max: 1.55
Current: 0.39

During the past 13 years, the highest EV-to-EBITDA of Ampio Pharmaceuticals was 1.55. The lowest was -12.89. And the median was -0.88.

FRA:APH0's EV-to-EBITDA is ranked better than
82.26% of 451 companies
in the Biotechnology industry
Industry Median: 9.01 vs FRA:APH0: 0.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-12), Ampio Pharmaceuticals's stock price is €3.62. Ampio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-10.226. Therefore, Ampio Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ampio Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Ampio Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals EV-to-EBITDA Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.88 -313.57 -98.10 0.45 0.22

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.37 0.22 0.32 0.22

Competitive Comparison of Ampio Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Ampio Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's EV-to-EBITDA falls into.



Ampio Pharmaceuticals EV-to-EBITDA Calculation

Ampio Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-3.407/-8.725
=0.39

Ampio Pharmaceuticals's current Enterprise Value is €-3.41 Mil.
Ampio Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ampio Pharmaceuticals  (FRA:APH0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ampio Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.62/-10.226
=At Loss

Ampio Pharmaceuticals's share price for today is €3.62.
Ampio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.226.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ampio Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals (FRA:APH0) Business Description

Traded in Other Exchanges
Address
373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.

Ampio Pharmaceuticals (FRA:APH0) Headlines

No Headlines